Compare Moderna, Inc. (MRNA) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Zoom Video Communications, Inc. — how do they compare? Moderna, Inc. trades at $220.82 (market cap $78.65B), while Zoom Video Communications, Inc. trades at $97.16 (market cap $27.62B). The key difference: Moderna, Inc. is far larger — about 2.8× Zoom Video Communications, Inc.'s market cap, and Moderna, Inc. is trading nearer its 52-week high, Zoom Video Communications, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Zoom Video Communications, Inc. for 92 Days on average.
| MRNA | ZM | |
|---|---|---|
Market Cap | $78.65B | $27.62B |
Volume | 37,373,437 | 3,913,188 |
Sector | Health | Technology |
52-Week High | $203.46 | $111.88 |
52-Week Low | $22.36 | $72.72 |
Typical Hold Time | 59 Days | 92 Days |
Enterprise Value | $74.80B | $20.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Zoom Communications (ZM) trades at $96.20, up 1.51% today, with a bullish technical signal from moving averages and a consensus analyst price target of $118.08. The company reported strong earnings beats in Q1 and Q2 2026, with net income reaching $1.01 billion in 2025 and a robust net income margin of 65.19%. Recent news highlights AI-driven product launches and board appointments, signaling strategic growth initiatives.
The outlook for ZM is positive, supported by solid profitability and Wall Street's buy ratings, but risks include competitive pressures and reliance on international sales. The stock's current valuation metrics, such as a P/E of 8.79, suggest potential upside if earnings growth continues, though investors should monitor execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
